Related Experiment Video

Updated: Jun 8, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Management of dyslipidemia in Cushing's syndrome

Yona Greenman1

  • 1Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. greenman@tasmc.health.gov.il

Neuroendocrinology
|September 11, 2010
PubMed

Insights

Cushing's syndrome frequently causes hyperlipidemia, a significant cardiovascular risk. Aggressive lipid management is crucial, with careful consideration of drug interactions during treatment for persistent hypercortisolism.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Cushing's syndrome is characterized by high prevalence of cardiovascular risk factors, including hypertension, hyperlipidemia, and glucose intolerance.
  • Lipid abnormalities affect 40-70% of patients, even those with subclinical disease, highlighting the systemic impact of cortisol excess.

Purpose of the Study:

  • To summarize the prevalence and management challenges of hyperlipidemia in Cushing's syndrome.
  • To emphasize the importance of aggressive lipid management in mitigating cardiovascular risks associated with this condition.

Main Methods:

  • Review of existing literature on lipid abnormalities in Cushing's syndrome.
  • Analysis of therapeutic challenges and drug interactions in managing hyperlipidemia in this patient population.

Main Results:

  • Surgical cure of Cushing's syndrome generally improves lipid profiles.
  • Medical treatments for persistent hypercortisolism present specific challenges, such as increased cholesterol with o,p'DDD and potential statin interactions with ketoconazole (CYP3A4 inhibitor).
  • Pravastatin is a preferred statin due to its different metabolic pathway compared to simvastatin and atorvastatin.

Conclusions:

  • Hyperlipidemia requires aggressive treatment in Cushing's syndrome due to associated cardiovascular morbidity and mortality.
  • Careful drug selection is necessary to manage hyperlipidemia, especially when using medications affecting cortisol levels or interacting with lipid-lowering agents.

Related Concept Videos

Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...